Baidu
map

JAHA:新型药物CM352能显著改善脑出血后神经功能的恢复

2017-06-05 MedSci MedSci原创

脑出血(ICH)是一类急性的神经系统疾病,死亡率高,预后差。除初次出血事件外,再出血和血肿扩张与这些患者的不良结局均有关。本研究旨在在胶原酶诱导的ICH大鼠模型中探索新的抗纤维蛋白溶解剂CM352(一种半衰期短的基质金属蛋白酶抑制剂)的早期止血和改善功能恢复的有效性。

脑出血(ICH)是一类急性的神经系统疾病,死亡率高,预后差。除初次出血事件外,再出血和血肿扩张与这些患者的不良结局均有关。本研究旨在在胶原酶诱导的ICH大鼠模型中探索新的抗纤维蛋白溶解剂CM352(一种半衰期短的基质金属蛋白酶抑制剂)的早期止血和改善功能恢复的有效性。

大鼠ICH模型通过纹状体注射胶原酶建立,建模成功1小时后分别给予静脉注射盐水(n=6)或CM352(1mg/kg,n=6),在T2加权(T2)磁共振图像上进行血肿(基线、建模3和24小时后)和损伤体积(14天后)的定量。神经功能的恢复通过Bederson 评分和圆柱测试进行评估(基线、24小时后和14天后)。结果表明CM352的早期治疗有助于减少3小时血肿扩张发生(p<0.01),降低的效果在建模24小时后更显着(p<0.01)。抗纤维蛋白溶解治疗后出血减少并伴随3小时时白细胞介素-6水平的降低(p<0.05),14天病变体积减小(p<0.01)。CM352可以显着降低建模24小时(p<0.01)和14天(p<0.01)感觉障碍的发生率,同样,也能减轻神经缺陷的发生率。此外, CM352的晚期(3小时)给药也能减轻病变和改善功能。

CM352作为新型的抗纤维蛋白溶解剂和基质金属蛋白酶抑制剂能显着减轻脑出血引起的血肿扩张和脑损伤,并有助于改善神经功能恢复。

原始出处:

Doi:https://doi.org/10.1161/JAHA.117.006042

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1267466, encodeId=c259126e466f3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jun 07 06:58:00 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422059, encodeId=d3be142205978, content=<a href='/topic/show?id=e5f0e42224f' target=_blank style='color:#2F92EE;'>#神经功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74222, encryptionId=e5f0e42224f, topicName=神经功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85503680375, createdName=lhlxtx, createdTime=Wed Jun 07 06:58:00 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486356, encodeId=d20b14863568e, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Wed Jun 07 06:58:00 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207090, encodeId=9a1320e090fb, content=希望临床实验顺利, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Tue Jun 06 06:41:31 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
    2017-06-07 zhaohui6731
  2. [GetPortalCommentsPageByObjectIdResponse(id=1267466, encodeId=c259126e466f3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jun 07 06:58:00 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422059, encodeId=d3be142205978, content=<a href='/topic/show?id=e5f0e42224f' target=_blank style='color:#2F92EE;'>#神经功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74222, encryptionId=e5f0e42224f, topicName=神经功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85503680375, createdName=lhlxtx, createdTime=Wed Jun 07 06:58:00 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486356, encodeId=d20b14863568e, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Wed Jun 07 06:58:00 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207090, encodeId=9a1320e090fb, content=希望临床实验顺利, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Tue Jun 06 06:41:31 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1267466, encodeId=c259126e466f3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jun 07 06:58:00 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422059, encodeId=d3be142205978, content=<a href='/topic/show?id=e5f0e42224f' target=_blank style='color:#2F92EE;'>#神经功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74222, encryptionId=e5f0e42224f, topicName=神经功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85503680375, createdName=lhlxtx, createdTime=Wed Jun 07 06:58:00 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486356, encodeId=d20b14863568e, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Wed Jun 07 06:58:00 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207090, encodeId=9a1320e090fb, content=希望临床实验顺利, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Tue Jun 06 06:41:31 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1267466, encodeId=c259126e466f3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jun 07 06:58:00 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422059, encodeId=d3be142205978, content=<a href='/topic/show?id=e5f0e42224f' target=_blank style='color:#2F92EE;'>#神经功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74222, encryptionId=e5f0e42224f, topicName=神经功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85503680375, createdName=lhlxtx, createdTime=Wed Jun 07 06:58:00 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486356, encodeId=d20b14863568e, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Wed Jun 07 06:58:00 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207090, encodeId=9a1320e090fb, content=希望临床实验顺利, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Tue Jun 06 06:41:31 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
    2017-06-06 meiliwuxian

    希望临床实验顺利

    0

相关资讯

Neurology:酒精摄入与脑出血风险分析!

该研究的结果表明罕见的和适度的饮酒对ICH风险具有潜在的保护效应。重度饮酒与ICH风险增加相关。民族/种族是酒精相关的ICH风险的一个重要因素;黑人和西班牙裔人重度饮酒可以显著增加非脑叶ICH风险。

Neurology:不同口服抗凝剂对脑出血的影响

非维生素K类抗凝药与维生素K类抗凝药对脑出血患者的死亡率,神经功能,脑出血体积与血肿扩大作用相似

Crit Care Med:脑出血患者连续输注高渗盐水治疗发生中度高血氯对患者预后的影响

持续静脉滴注3%高渗盐水治疗期间发生中度高血氯的患者住院死亡率较高,中度高血氯可以独立预测住院死亡率。这些结果表明在高渗盐水治疗期间应对血氯值进行密切监测,因为其中度升高可能会影响脑出血患者的结局。

Stroke: 脑出血后监测水肿的发展过程:改善预后

背景:脑出血后水肿可能加重预后。研究者评估了脑出血的自然病程,影响脑水肿的因素及其与预后的相关性。方法: 研究者应用半自动测面积法测定赫尔辛基ICH研究中ICH患者的脑水肿体积。研究者评估水肿延伸距离(EED)与ICH开始时间的相关性,建立长达3周水肿的发展轨迹模型。研究者确定72小时的EED,并且识别与水肿快速增长的临床和影像学特点。校正ICH的预后预测因子,应用Logistic回归分析EED和

Stroke:我国急性缺血性卒中患者血栓抽吸后脑出血发生率达16%

4月3日,南京军区南京总医院神经内科刘新峰、徐格林教授等领衔开展的ACTUAL研究(急性前循环缺血性卒中血管内治疗注册研究)组在Stroke杂志上发表的最新研究成果表明,在我国接受血栓抽吸72 小时内的急性缺血性卒中患者中,症状性脑出血的发生率达16%,这一比例明显高于此前公布的相关研究。

Stroke:ECASS III和HBC脑出血分类标准有何差异?

由此可见,通过ECASS III和HBC标准进行ICH的分类具有明显的差异。在科学出版物的解释和比较中需要特别注意这些差异。

Baidu
map
Baidu
map
Baidu
map